Armata Highlights AP-SA02 Progress Amid Earnings Release Delay

Armata Pharmaceuticals ( (ARMP) ) just unveiled an update.

On March 19, 2026, Armata Pharmaceuticals said it will delay releasing its fourth-quarter and full-year 2025 financial results while it completes its reporting, but still expects to file its annual report by the March 31 deadline. At the same time, the company detailed a series of clinical, regulatory and manufacturing milestones for its lead bacteriophage candidate AP-SA02 targeting complicated Staphylococcus aureus bacteremia, underlining its focus on advancing late-stage assets despite the reporting delay.

The U.S. Food and Drug Administration has granted AP-SA02 Qualified Infectious Disease Product status for intravenous adjunct treatment of complicated S. aureus bacteremia caused by both methicillin-sensitive and methicillin-resistant strains, making it eligible for extended market exclusivity and other development incentives. Armata has also requested Fast Track designation and, following an End-of-Phase 2 interaction in which the FDA deemed its Phase 2a diSArm data sufficient, plans to launch a Phase 3 superiority trial in the second half of 2026, guided by FDA input on study design, manufacturing controls and eventual biologics license submission.

The company reported that its Los Angeles cGMP manufacturing facility has now been formally commissioned, with full production runs completed to support upcoming clinical trials and potential commercialization of its phage therapies. The roughly 56,000-square-foot site, which includes extensive clean-room space and quality labs, bolsters Armata’s ability to secure supply for its own programs and potentially serve as a partner or contract manufacturer in a field where domestic capacity and reliable production are increasingly viewed as strategic assets.

Armata highlighted previously presented positive Phase 2a diSArm results, where AP-SA02 combined with best available antibiotic therapy showed higher and earlier cure rates versus antibiotics alone, with a 100% response rate without relapse at key follow-up points and encouraging safety across MRSA and MSSA infections. Patients receiving AP-SA02 also demonstrated trends toward faster normalization of biomarkers, quicker clearance of blood cultures and shorter intensive care and hospital stays, reinforcing the program’s potential to redefine the treatment standard in a high-mortality indication.

The company has been actively engaging the infectious disease community through a key opinion leader webinar on complicated S. aureus bacteremia and the potential role of AP-SA02, featuring external academic experts. It is also continuing basic and translational research collaborations to deepen understanding of phage structure and function, aiming to support the development of future phage-based antibacterial therapies and broaden its long-term pipeline beyond the current lead program.

The most recent analyst rating on (ARMP) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Armata Pharmaceuticals stock, see the ARMP Stock Forecast page.

Spark’s Take on ARMP Stock

According to Spark, TipRanks’ AI Analyst, ARMP is a Neutral.

The score is held down primarily by weak financial performance—declining revenue, large losses, sustained cash burn, and a strained capital structure with high debt and negative equity. Technicals are neutral-to-soft (near-term below key moving averages), while corporate events provide a meaningful offset via Phase 3 regulatory momentum and improved debt maturity timing; valuation remains constrained by negative earnings and no dividend.

To see Spark’s full report on ARMP stock, click here.

More about Armata Pharmaceuticals

Armata Pharmaceuticals, Inc. is a late clinical-stage biotechnology company developing high-purity, pathogen-specific bacteriophage therapeutics to treat antibiotic-resistant and difficult-to-treat bacterial infections. Its pipeline targets pathogens such as Pseudomonas aeruginosa and Staphylococcus aureus, supported by in-house current Good Manufacturing Practice capabilities to scale from clinical development to full commercialization.

The company operates a state-of-the-art cGMP facility in Los Angeles with clean rooms, automated fill-and-finish, and quality control laboratories to back future trials and potential commercial supply. This infrastructure positions Armata to pursue partnering and contract manufacturing opportunities while aligning with U.S. policy priorities to onshore essential medicine production and address the growing antimicrobial resistance crisis.

Average Trading Volume: 46,065

Technical Sentiment Signal: Buy

Current Market Cap: $310.9M

See more insights into ARMP stock on TipRanks’ Stock Analysis page.